Home/Investors/Kleiner Perkins

Kleiner Perkins

Biotech Investor · 3 portfolio companies

Portfolio

3

Combined Value

$1.4B

Focus Areas

11

Top Stage

Phase 2

Investment Focus

Neuropsychiatry Neurology Autism Spectrum Disorder Schizophrenia Depression Alzheimer's Disease Autoimmune Diseases Immunology Metabolic Disease Dermatology Oncology

Portfolio Companies

Company	Stage	Valuation	Focus
MapLight Therapeutics	Phase 2	$796.8M	Neuropsychiatry, Neurology
Kyverna Therapeutics	Phase 1/2	$473.3M	Autoimmune Diseases, Immunology
Sagimet Biosciences	Phase 3	$157.1M	Metabolic Disease, Dermatology

Frequent Co-Investors

Westlake Village BioPartners2 shared Arch Venture Partners1 shared Venrock1 shared Gilead Sciences1 shared Fidelity Investments1 shared Redmile Group1 shared Vida Ventures1 shared GordonMD1 shared